Literature DB >> 11433275

The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors.

H Xia1, Q Mao, B L Davidson.   

Abstract

Treatment of inherited genetic diseases of the brain remains an intractable problem. Methods to improve the distribution of enzymes that are injected or expressed from transduced cells will be required for many human brain therapies. Recent studies showed that a peptide, the protein transduction domain (PTD) from HIV Tat, could improve the distribution of cytoplasmic reporter proteins when administered systemically as fusion proteins or cross-linked chimeras. The utility of this motif for noncytoplasmic proteins has not been determined. Here, we tested how the Tat motif affected uptake and biodistribution of the lysosomal enzyme beta-glucuronidase, the protein deficient in the disease mucopolysaccharidosis VII, when expressed from viral vectors. The Tat motif allowed for mannose-6-phosphate (M6P) independent uptake in vitro and significantly increased the distribution of beta-glucuronidase secreted from transduced cells after intravenous or direct brain injection in mice of recombinant vectors. Thus, enzymes modified to contain protein transduction motifs may represent a general strategy for improving the distribution of secreted proteins following in vivo gene transfer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433275     DOI: 10.1038/90242

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  38 in total

Review 1.  Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.

Authors:  William S Sly; Carole Vogler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

2.  Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.

Authors:  Koji Higuchi; Makoto Yoshimitsu; Xin Fan; Xiaoxin Guo; Vanessa I Rasaiah; Jennifer Yen; Chuwa Tei; Toshihiro Takenaka; Jeffrey A Medin
Journal:  Mol Med       Date:  2010-02-17       Impact factor: 6.354

3.  Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Hanne M Nielsen; Heinz-Georg Jahnke; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

4.  Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Ulrike Krauss; Roman Muff; Martina Meinecke; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 5.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

6.  Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity.

Authors:  Ying Shen; William Yu; John G Hay; Harald Sauthoff
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

7.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

Review 8.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

9.  LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription.

Authors:  Amar N Mirza; Siegen A McKellar; Nicole M Urman; Alexander S Brown; Tyler Hollmig; Sumaira Z Aasi; Anthony E Oro
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

10.  Discovery and characterization of a new cell-penetrating protein.

Authors:  Rudo L Simeon; Ana Maria Chamoun; Thomas McMillin; Zhilei Chen
Journal:  ACS Chem Biol       Date:  2013-10-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.